Dr. Roman Bronfenbrener, MD

Dr. Bronfenbrener practices at Dermatology Specialists of Pennsylvania in Southampton, Pennsylvania.

Dr. Bronfenbrener's NPI, 1134488638, was assigned on May 4, 2012. Dr. Bronfenbrener graduated from Rutgers Robert Wood Johnson Medical School in 2012. Dr. Bronfenbrener holds Pennsylvania license MD457011.

Dr. Bronfenbrener's primary practice is Dermatology Specialists of Pennsylvania, at 1122 Street Rd, Southampton, PA 18966 in Bucks County. The practice phone is (415) 802-1310.

Dr. Bronfenbrener's primary practice is Dermatology Specialists of Pennsylvania in Southampton, Pennsylvania. Dr. Bronfenbrener is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Pennsylvania Dermatology Specialists. Dmand AI also links Dr. Bronfenbrener to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bronfenbrener practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Bronfenbrener's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Bronfenbrener is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Bronfenbrener's licenses on file in 2 states: Pennsylvania and New York.

CMS data shows 50,478 Medicare services from Dr. Bronfenbrener across 66 procedure codes in 2024, for 1,657 Medicare patients. Medicare paid $1,404,828 for them.

CMS counts 1,657 Medicare patients who saw Dr. Bronfenbrener in 2024. The largest group is 65 to 74, with 650 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bronfenbrener's median patient age at 71, with 52% women.

In 2024, Dr. Bronfenbrener wrote 8,838 Medicare Part D claims for 1,254 patients. 93% of them were for generic drugs. CMS names the drug for 8,606 of them, across 47 drugs with 11 or more claims each, at $1,230,956 in total drug cost. In 2023, CMS named 8,003 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Bronfenbrener for performance year 2024, reported as part of a group. Dr. Bronfenbrener accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 5,384 procedures of removal of skin lesions by Dr. Bronfenbrener, more than 99% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Bronfenbrener, published from 2012 to 2023. 2013 was the busiest year, with 2. The most frequent topics are Biopsy, Dermatology and Diagnosis, Differential. Dr. Bronfenbrener has published most often in Am J Dermatopathol. Dr. Bronfenbrener's most frequent co-authors are Susan Pei, James Abbott, MD and Jean L. Bolognia, MD.

CMS Open Payments shows 2,554 general payments to Dr. Bronfenbrener from 52 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 63% of the total. Galderma Laboratories, L.P. paid the most, $16,068.

Dr. Bronfenbrener graduated from Rutgers Robert Wood Johnson Medical School in 2012. Dr. Bronfenbrener is a member of AOA, AAD, AMA, ASDS and International Dermoscopy Society.

Dr. Bronfenbrener is in network with 20 carriers, including Aetna, HCSC and Highmark. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.